Zobrazeno 1 - 10
of 60
pro vyhledávání: '"Matthew L Rizk"'
Autor:
Sébastien Bihorel, Youfang Cao, Akshita Chawla, Ruthie Birger, Brian M. Maas, Wei Gao, Stefan Roepcke, Susanne Sardella, Rebecca Humphrey, Sindhuri Kondragunta, Bhuvana Jayaraman, Monika Martinho, Wendy Painter, George Painter, Wayne Holman, Carisa De Anda, Michelle L. Brown, Matthew G. Johnson, Amanda Paschke, Matthew L. Rizk, Julie A. Stone
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 12, Iss 12, Pp 1859-1871 (2023)
Abstract Effective antiviral treatments for coronavirus disease 2019 (COVID‐19) are needed to reduce the morbidity and mortality associated with severe acute respiratory syndrome‐coronavirus 2 (SARS‐CoV‐2) infection, particularly in patients
Externí odkaz:
https://doaj.org/article/8cddadd8bcca434f80fe87480a247f8a
Autor:
Matthew L Rizk, James C Liao
Publikováno v:
PLoS ONE, Vol 4, Iss 9, p e6903 (2009)
Ensemble Modeling (EM) is a recently developed method for metabolic modeling, particularly for utilizing the effect of enzyme tuning data on the production of a specific compound to refine the model. This approach is used here to investigate the prod
Externí odkaz:
https://doaj.org/article/0ac85203a2fa403f8d332a3be3544987
Autor:
Brian M. Maas, Julie Strizki, Randy R. Miller, Sushma Kumar, Michelle Brown, Matthew G. Johnson, Mickie Cheng, Carisa De Anda, Matthew L. Rizk, Julie A. Stone
Publikováno v:
Clinical and Translational Science, Vol 17, Iss 2, Pp n/a-n/a (2024)
Abstract Molnupiravir is an oral prodrug of the broadly active, antiviral ribonucleoside analog N‐hydroxycytidine (NHC). The primary circulating metabolite NHC is taken up into cells and phosphorylated to NHC‐triphosphate (NHC‐TP). NHC‐TP ser
Externí odkaz:
https://doaj.org/article/80235adabbc14c2b94f7c558ebb6cf63
Autor:
Paul van den Berg, Wei Gao, Maurice J. Ahsman, Leticia Arrington, Filippos Kesisoglou, Randy Miller, Teun M. Post, Matthew L. Rizk
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 10, Iss 7, Pp 658-670 (2021)
Abstract Uprifosbuvir is a uridine nucleoside monophosphate prodrug inhibitor of the hepatitis C virus NS5B RNA polymerase. To quantitatively elucidate key metabolic pathways, assess the link between unmeasurable effect site concentrations and viral
Externí odkaz:
https://doaj.org/article/5efa895ab7f349ba8e6d77672c190469
Autor:
Akshita Chawla, Ruthie Birger, Hong Wan, Youfang Cao, Brian M. Maas, Amanda Paschke, Carisa De Anda, Matthew L. Rizk, Julie A. Stone
Publikováno v:
Clinical Pharmacology & Therapeutics. 113:1337-1345
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3562415a8289c9e76a19e9c4b7178634
https://doi.org/10.1002/cpt.2895
https://doi.org/10.1002/cpt.2895
Autor:
Jason A Roberts, David P Nicolau, Ignacio Martin-Loeches, C Andrew Deryke, Maria C Losada, Jiejun Du, Munjal Patel, Matthew L Rizk, Amanda Paschke, Luke F Chen
Publikováno v:
JAC-Antimicrobial Resistance. 5
ObjectivesTo assess the relationship between renal function and efficacy/safety of imipenem/cilastatin/relebactam for the treatment of hospital-acquired/ventilator-associated pneumonia (HABP/VABP) from RESTORE-IMI 2 and determine the PTA.MethodsAdult
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ed1025016a6f95ac66a94ea0ee5f5659
https://doi.org/10.1093/jacamr/dlad011
https://doi.org/10.1093/jacamr/dlad011
Autor:
Katherine Young, Ferdous Gheyas, Francesco Bellanti, Pooja Kulkarni, David W. Hilbert, Munjal Patel, William Copalu, Matthew L. Rizk, Naveen M. Daryani, Nadia Z. Noormohamed
Publikováno v:
Clinical and Translational Science, Vol 15, Iss 2, Pp 396-408 (2022)
In the phase III RESTORE‐IMI 2 study (ClinicalTrials.gov: NCT02493764), the combination antibacterial agent imipenem/cilastatin/relebactam (IMI/REL) demonstrated noninferiority to piperacillin/tazobactam for the end points of all‐cause mortality
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::568dd7388abaccc3b763d679304fd2a7
https://doi.org/10.1111/cts.13158
https://doi.org/10.1111/cts.13158
Autor:
Matthew L. Rizk, Paul van den Berg, Maurice J. Ahsman, Teun M. Post, Leticia Arrington, Filippos Kesisoglou, Wei Gao, Randy R. Miller
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 10, Iss 7, Pp 658-670 (2021)
CPT: Pharmacometrics & Systems Pharmacology
CPT: Pharmacometrics & Systems Pharmacology
Uprifosbuvir is a uridine nucleoside monophosphate prodrug inhibitor of the hepatitis C virus NS5B RNA polymerase. To quantitatively elucidate key metabolic pathways, assess the link between unmeasurable effect site concentrations and viral load redu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eff3cb7c0a6346088a2ae3263924ec94
https://doi.org/10.1002/psp4.12644
https://doi.org/10.1002/psp4.12644
Autor:
Jenny Huimin Zheng, David Wesche, Philip Sabato, Radojka M. Savic, Abhay Joshi, Melanie R. Nicol, Jack Cook, Matthew L. Rizk
Publikováno v:
Clinical Pharmacology and Therapeutics
Clinical pharmacology and therapeutics, vol 108, iss 6
Clinical Pharmacology & Therapeutics
Clinical pharmacology and therapeutics, vol 108, iss 6
Clinical Pharmacology & Therapeutics
Chloroquine and hydroxychloroquine are quinoline derivatives used to treat malaria. To date, these medications are not approved for the treatment of viral infections and there are no well‐controlled, prospective, randomized clinical studies or evid
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e700c49a20fb9c56ff9a1b075555e356
https://doi.org/10.1002/cpt.1993
https://doi.org/10.1002/cpt.1993
Autor:
Nicholas A. Kartsonis, Antoine Roquilly, Robert W. Tipping, Luke F Chen, Aileen David-Wang, Richard G. Wunderink, Joan R. Butterton, Daniel Gonzalez, Jiejun Du, Munjal Patel, Keith S Kaye, Katherine Young, Ivan Titov, Michelle L Brown, Maria C Losada, Amanda Paschke, Helen W. Boucher, Matthew L. Rizk
Publikováno v:
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
Background Imipenem combined with the β-lactamase inhibitor relebactam has broad antibacterial activity, including against carbapenem-resistant gram-negative pathogens. We evaluated efficacy and safety of imipenem/cilastatin/relebactam in treating h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6088cad957d7d5ee0a356936d00a1aec
https://doi.org/10.1093/cid/ciaa803
https://doi.org/10.1093/cid/ciaa803